Natera, Inc. is a diagnostics company that develops and commercializes non-invasive methods for analyzing DNA. The company's core technology is based on cell-free DNA (cfDNA) testing, which it applies across three primary clinical segments: women's health, oncology, and organ health. In women's health, Natera offers Panorama, a non-invasive prenatal test (NIPT), and Horizon, an advanced carrier screening test. In oncology, its flagship product is Signatera, a personalized circulating tumor DNA (ctDNA) blood test used for molecular residual disease (MRD) assessment, early recurrence monitoring, and treatment response evaluation. For organ health, the company provides Prospera, a test designed to assess active rejection in solid organ transplant patients.
Natera generates revenue primarily through the sale of these proprietary testing products and services to hospitals, physicians, cancer centers, and specialty clinics. In 2025, the company processed approximately 3.5 million tests, generating over $2.3 billion in revenue, almost entirely from product sales. The company operates CAP-accredited and CLIA-certified laboratories in Austin, Texas, and San Carlos, California, where it processes the tests and turns genetic data into actionable reports for healthcare providers. Natera's competitive position is driven by its advanced bioinformatics algorithms and extensive clinical validation, which support the integration of its tests into standard medical care.
